Solid Biosciences Inc. (SLDB)
NMS – Real Time Price. Currency in USD
7.72
+0.04 (0.52%)
At close: May 12, 2026, 4:00 PM EDT
7.30
-0.42 (-5.44%)
Pre-market: May 13, 2026, 7:02 AM EDT
Find any stock by ticker or company name

NMS – Real Time Price. Currency in USD
7.72
+0.04 (0.52%)
At close: May 12, 2026, 4:00 PM EDT
7.30
-0.42 (-5.44%)
Pre-market: May 13, 2026, 7:02 AM EDT
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
| Name | Position |
|---|---|
| Dr. Gabriel Brooks M.D. | Chief Medical Officer |
| Dr. Jessie Hanrahan Ph.D. | Chief Regulatory & Preclinical Operations Officer |
| Mr. Alexander G. Cumbo | President, CEO & Director |
| Mr. David Tyronne Howton Jr., J.D. | COO & Secretary |
| Mr. Ian F. Smith A.C.A., C.P.A. | Executive Chair |
| Mr. Ilan Ganot | Co-founder, Strategic Advisor to the CEO & Director |
| Date | Type | Document |
|---|---|---|
| 2026-05-12 | 10-Q | sldb-20260331.htm |
| 2026-04-23 | DEF 14A | sldb-20260422.htm |
| 2026-04-23 | ARS | ars_2025.pdf |
| 2026-04-10 | 8-K | sldb-20260410.htm |
| 2026-03-27 | CORRESP | filename1.htm |
| 2026-03-19 | S-8 | sldb-20260318.htm |
| 2026-03-19 | S-3 | d125122ds3.htm |
| 2026-03-12 | 8-K | sldb-20260311.htm |
| 2026-03-06 | 8-K | d81855d8k.htm |
| 2025-11-03 | 10-Q | sldb-20250930.htm |
| Mr. Kevin Tan C.F.A. | CFO & Treasurer |
| Mr. Paul Herzich | Chief Technology Officer |
| Ms. Annie Ganot | Co-Founder & VP of Patient Advocacy |
| Ms. Nicole Anderson | Senior Director of Investor Relations & Corporate Communications |